Privia Health Group (PRVA) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
8 Jul, 2026Executive summary
Achieved strong financial and operational performance in Q3 2024, with implemented providers up 13.1% to 4,642 and attributed lives up 14.0% to 1,247,000 year-over-year.
Expanded into Indiana with a new multi-specialty practice, now operating in 14 states and DC, and record new provider signings year-to-date.
Delivered $176.6 million in MSSP 2023 shared savings, up 34.1% from 2022, with 81% of lives in downside risk tracks.
Maintained high provider retention (98%+) and a Net Promoter Score of 85, serving over 5.1 million patients and 1.2 million attributed lives.
Net income for Q3 2024 was $3.5 million, down from $5.6 million in Q3 2023, primarily due to higher operating expenses and stock-based compensation.
Financial highlights
Q3 2024 revenue was $437.9 million, up 4.9% year-over-year; practice collections reached $739.9 million, up 2.3% year-over-year.
Adjusted EBITDA for Q3 2024 was $23.6 million (23.3% margin), up 25.8% year-over-year; care margin was $101.4 million, up 10.2%.
Year-to-date free cash flow was $87 million, pro forma for net CMS cash, with a pro forma cash balance of $473.5 million and no debt.
Adjusted net income per diluted share for Q3 2024 was $0.20, up from $0.17 in Q3 2023.
Gross profit for Q3 2024 was $99.9 million, up from $90.6 million in Q3 2023.
Outlook and guidance
Raised 2024 guidance to the high end or above for all metrics, including attributed lives above 1.2 million, practice collections of $2.875 billion, GAAP revenue of $1.675 billion, care margin of $400 million, and adjusted EBITDA of $90 million.
Targeting annual adjusted EBITDA growth of 20% or greater, with ~90% of full-year adjusted EBITDA expected to convert to free cash flow.
Confident in continued organic provider growth and operating leverage into 2025, despite ongoing headwinds in Medicare Advantage.
Practice collections guidance includes a $198 million year-over-year impact from renegotiated Medicare Advantage capitation agreements.
Management expects cash on hand and operating cash flows to be sufficient for both short- and long-term capital needs.
Latest events from Privia Health Group
- Q3 2025 revenue up 32.5%, net income up 94.1%, and FY 2025 guidance raised after strong growth.PRVA
Q3 20251 Jul 2026 - Q1 revenue up 25.8%, adjusted EBITDA up 36.3%, and guidance raised for attributed lives.PRVA
Q1 202613 May 2026 - 2025 outperformance and 2026 guidance highlight robust growth, cash flow, and strategic expansion.PRVA
Q4 20256 Apr 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with board support.PRVA
Proxy filing2 Apr 2026 - Proxy covers director elections, executive pay, auditor ratification, and strong ESG and governance.PRVA
Proxy filing2 Apr 2026 - Q2 2024 delivered strong growth, raised guidance, and maintained a robust cash position.PRVA
Q2 20242 Feb 2026 - Tech-enabled platform drives profitable growth and high retention in value-based care.PRVA
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Record provider adds, robust cash flow, and expanding value-based care support 20%+ EBITDA growth.PRVA
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - 2024 outperformed guidance; 2025 targets further growth amid value-based care challenges.PRVA
Q4 202416 Dec 2025